ALK

Allergy solutions for life

Take back control

More than 500 million people worldwide have allergies. Many of them suffer in silence because the way ahead is too confusing.

Watch the video

News

See all

Post date
08/16/2021

Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff

Read more
Post date
08/11/2021

Six-month interim report (Q2) 2021

Read more
Post date
08/09/2021

ALK upgrades its full-year financial outlook

Read more
Post date
08/05/2021

Change to ALK’s Board of Directors

Read more
Post date
08/05/2021

Release date of six-month interim report (Q2) 2021 for ALK and audio cast

Read more
Post date
07/30/2021

ALK and Grandpharma team up to market the first adrenaline autoinjector in China

Read more
Post date
07/10/2021

New, large, ‘real-world evidence’ study by ALK of AIT’s long-term effects on allergy and asthma presented at EAACI Congress

Read more
Post date
05/10/2021

Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff

Read more
Post date
05/05/2021

Three-month interim report (Q1) 2021

Read more

Strategy update: Focus areas during 2021-23

Having made the necessary, significant investments to transform ALK, we are now entering the next phase of the company’s development, where we must carefully work to sustain long-term growth, while also returning ALK to profitability.

ALK in brief

Allergy at a glance

Allergic rhinitis - popularly known as hay fever - is a widespread chronic disease. It is estimated to affect one in four persons in the industrialised world.

Our solutions

By collecting information and the latest and most trusted solutions together in one place, we want to make allergy surprisingly simple to manage.